Pfizer and BioNTech announced early positive data from an ongoing Phase 1/2 study of mRNA-based vaccine candidate against SARS-COV-2.

Medical Information
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?